VD/VDR-vd-vdr.com

CHIR-124 is a novel and potent chk1 inhibitor with an IC50 of 0.3 nM. Chk1 kinase is a critical regulator of both the S and G2/M phase cell cycle checkpoints in response to DNA damage. CHIR-124 has been shown that inhibitors of chk1 can selectively sensitize tumor cells with mutant p53 to genotoxic agents.

June 21, 2017

prudect name : CHIR-124 is a novel and potent chk1 inhibitor with an IC50 of 0.3 nM. Chk1 kinase is a critical regulator of both the S and G2/M phase…

📌

0💬 read more

prudect name : Cefoselis sulfateSynonyms: CAS NO: 122841-12-7Molecular Formula: C19H22N8O6S2.H2O4S;C19H24N8O10S3Molecular Weight: 620.64Purity: 98% minSolubility: Storage:

prudect name : Cefoselis sulfate Synonyms: CAS NO: 122841-12-7Molecular Formula: C19H22N8O6S2.H2O4S;C19H24N8O10S3Molecular Weight: 620.64Purity: 98% minSolubility: Storage: −20°C LY411575 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18508551

📌

0💬 read more

XL-184 free base (Cabozantinib) is a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively. In cells XL-184 free base (Cabozantinib) is also very potent, with IC50 under 10 nM for VEGFR2, MET, Kit and FLT3-ITD mechanistic assays. In in vitro angiogenesis assays, XL-184 free base (Cabozantinib) exhibits single-digit nanomolar potency. In mouse xenograft models, XL-184 free base (Cabozantinib), dosed orally, demonstrated dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature and extensive tumor cell apoptosis.

prudect name : XL-184 free base (Cabozantinib) is a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for…

📌

0💬 read more

Cyclopamine inhibits the hedgehog signaling pathway (Hh) by influencing the balance between the active and inactive forms of the Smoothened protein. The hedgehog signaling pathway carries out important functions in embryonic development and when it goes awry, deformities can occur. However, errant activation of the pathway can also trigger cancer in adult humans.

prudect name : Cyclopamine inhibits the hedgehog signaling pathway (Hh) by influencing the balance between the active and inactive forms of the Smoothened protein. The hedgehog signaling pathway carries out…

📌

0💬 read more

prudect name : Cilastatin sodiumSynonyms: CAS NO: 81129-83-1Molecular Formula: C16H25N2NaO5SMolecular Weight: 380.43Purity: ≥99%Solubility: Storage: −20°C

prudect name : Cilastatin sodium Synonyms: CAS NO: 81129-83-1Molecular Formula: C16H25N2NaO5SMolecular Weight: 380.43Purity: ≥99%Solubility: Storage: −20°C 2 years LBH-589 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18508453

📌

0💬 read more

prudect name : CamptothecinSynonyms: CAS NO: 7689-3-4Molecular Formula: C20H16N2O4Molecular Weight: 348.36Purity: ≥99%Solubility: Storage: −20°C

prudect name : Camptothecin Synonyms: CAS NO: 7689-3-4Molecular Formula: C20H16N2O4Molecular Weight: 348.36Purity: ≥99%Solubility: Storage: −20°C 2 years BIBW-2992 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18508405

📌

0💬 read more

CW-069 is a novel and allosteric inhibitor of the microtubule motor protein HSET with IC50 value of 75 ¡À 20 ¦ÌM; shows statistically significant selectivity over KSP.

prudect name : CW-069 is a novel and allosteric inhibitor of the microtubule motor protein HSET with IC50 value of 75 ¡À 20 ¦ÌM; shows statistically significant selectivity over KSP.CW069;CW-069…

📌

0💬 read more

CUDC-907 is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, CUDC-907 inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types. This may prevent growth of PI3K and/or HDAC-expressing tumor cells. CUDC-907 shows an increased inhibition of tumor cell growth and induction of apoptosis when compared to inhibitors that target either PI3K or HDAC. Check for active clinical trials or closed clinical trials using this agent.

prudect name : CUDC-907 is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, CUDC-907…

📌

0💬 read more

prudect name : CabazitaxelSynonyms: CAS NO: 183133-96-2Molecular Formula: C45H57NO14Molecular Weight: 835.93Purity: 98% minSolubility: In DMSOStorage:

prudect name : Cabazitaxel Synonyms: CAS NO: 183133-96-2Molecular Formula: C45H57NO14Molecular Weight: 835.93Purity: 98% minSolubility: In DMSOStorage: -20°C AT-9283 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18508352

📌

0💬 read more

prudect name : Cabazitaxel N-1Synonyms: CAS NO: 1354900-66-5Molecular Formula: C47H59NO15Molecular Weight: Purity: 98% minSolubility: In

prudect name : Cabazitaxel N-1 Synonyms: CAS NO: 1354900-66-5Molecular Formula: C47H59NO15Molecular Weight: Purity: 98% minSolubility: In DMSOStorage: -20°C JIB04 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18508252

📌

0💬 read more